AI Article Synopsis

  • - This study analyzed how brentuximab vedotin (BV), an antibody-drug conjugate, behaves in the body (pharmacokinetics) and how it affects response rates in patients with blood cancers, including both adults and children.
  • - It involved data from multiple studies, showing that the drug's exposure levels were similar in adolescents (12-18 years) compared to adults, but lower in younger children (2-12 years), with a noted overall response rate of 60% in the younger group.
  • - The findings suggest that the dosing of BV should be based on body weight rather than age, as no significant differences in effectiveness or severe side effects were found between the age groups.

Article Abstract

Aims: We studied the pharmacokinetics and exposure-response relationships of the brentuximab vedotin (BV) antibody-drug conjugate (ADC) and unconjugated monomethyl auristatin E in haematologic malignancies.

Methods: This population pharmacokinetic analysis included data from five adult and three paediatric studies. Exposures in virtual adult and paediatric populations following BV 1.8 mg/kg (maximum 180 mg) intravenously every 3 weeks were simulated. Clinical endpoints included overall response rate, grade ≥2 peripheral neuropathy (PN) and grade ≥3 neutropenia.

Results: BV ADC exhibited linear pharmacokinetics, well-described by a three-compartment model, with body weight being the only significant covariate for exposure. Monomethyl auristatin E exhibited time-varying formation rate. Simulated steady-state BV ADC exposures in patients aged 12 to <18 years were similar to those of adult patients, but 23%-38% lower in patients aged 2 to <12 years. Despite lower exposure, clinical activity was observed with BV 1.8 mg/kg every 3 weeks in those aged 2 to <12 years (overall response rate: 2 to <12 years, 60%; 12 to <18 years, 43%). In adult, but not paediatric patients, increased BV ADC exposures were associated with grade ≥2 PN and grade ≥3 neutropenia occurrence.

Conclusions: BV pharmacokinetics in adult and paediatric patients were consistent. BV ADC exposures were lower in patients aged 2 to <12 years vs. ≥12 years, but no apparent clinically relevant differences in efficacy, grade ≥2 PN or grade ≥3 neutropenia were observed. These data support body weight-based dosing of BV in patients irrespective of age; thus, dose adjustment in those 2 to <12 years does not appear warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.16128DOI Listing

Publication Analysis

Top Keywords

time-varying brentuximab
4
brentuximab vedotin
4
vedotin pharmacokinetics
4
pharmacokinetics weight-based
4
weight-based dosing
4
dosing paediatric
4
paediatric patients
4
patients despite
4
despite lower
4
lower exposure
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!